Video

Bausch + Lomb: clinical trial, pipeline updates for 2021

Author(s):

Sheryl Stevenson,Alex Delaney-Gesing
Conferences|ASCRS

Yolande Barnard, vice president and general manager of U.S. Pharmaceuticals at Bausch + Lomb, shares an update on the company's latest treatment for patients with DED associated with MGD as well as an investigational drug for the treatment of macular edema associated with uveitis.

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Related Content
ASRS 2025: Dropless vitrectomy with suprachoroidal triamcinolone-moxifloxacin
August 23rd 2025

ASRS 2025: Dropless vitrectomy with suprachoroidal triamcinolone-moxifloxacin

3 Things You Should Know About the GA Pipeline
August 23rd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: Ophthalmology Times) From firsts to the future: A pioneer's perspective on ophthalmology
August 23rd 2025

From firsts to the future: A pioneer's perspective on ophthalmology

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 23rd 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs
August 23rd 2025

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight
August 23rd 2025

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

© 2025 MJH Life Sciences

All rights reserved.